Drug Profile
Pradefovir - Ligand Pharmaceuticals
Alternative Names: Hepavir B; ICN-2001-3; MB-06866; MB-6866; Pradefovir mesylate; Remofovir; Remofovir mesylate; UNII-GZE85Q9Q61Latest Information Update: 27 Dec 2023
Price :
$50
*
At a glance
- Originator Metabasis Therapeutics
- Developer Ligand Pharmaceuticals; Valeant Pharmaceuticals International; Xian Xintong Pharmaceutical Research
- Class Adenine nucleotides; Antivirals; Organophosphorus compounds; Purines; Small molecules
- Mechanism of Action DNA-directed DNA polymerase inhibitors; Hepatitis B virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preregistration Hepatitis B
Most Recent Events
- 10 Nov 2023 Efficacy and adverse events data from a phase III trial in Hepatitis B presented at the 74th Annual Meeting of the American Association for the Study of Liver Disease (AASLD-2023)
- 09 Aug 2023 Preregistration for Hepatitis B in China (PO)
- 09 Aug 2023 Pradefovir receives priority review status for hepatitis B virus in China